Free Trial

Oragenics (OGEN) Competitors

Oragenics logo
$0.19 +0.00 (+1.20%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$0.19 0.00 (-0.15%)
As of 08:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OGEN vs. UPXI, MBRX, NRSN, INAB, FLGC, BCDA, GOVX, EQ, EDSA, and LPTX

Should you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include Upexi (UPXI), Moleculin Biotech (MBRX), NeuroSense Therapeutics (NRSN), IN8bio (INAB), Flora Growth (FLGC), BioCardia (BCDA), GeoVax Labs (GOVX), Equillium (EQ), Edesa Biotech (EDSA), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical products" industry.

Oragenics vs.

Oragenics (NYSE:OGEN) and Upexi (NASDAQ:UPXI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, community ranking, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Oragenics has higher earnings, but lower revenue than Upexi.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oragenics$40K104.31-$20.66M-$1.12-0.17
Upexi$16.56M1.17-$23.66MN/AN/A

Upexi received 3 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 42.86% of users gave Upexi an outperform vote while only 0.00% of users gave Oragenics an outperform vote.

CompanyUnderperformOutperform
OragenicsOutperform Votes
No Votes
Underperform Votes
55
100.00%
UpexiOutperform Votes
3
42.86%
Underperform Votes
4
57.14%

18.7% of Oragenics shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 4.9% of Oragenics shares are owned by company insiders. Comparatively, 31.6% of Upexi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Oragenics has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Upexi has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500.

Upexi's return on equity of 0.00% beat Oragenics' return on equity.

Company Net Margins Return on Equity Return on Assets
OragenicsN/A -2,087.95% -486.56%
Upexi N/A N/A N/A

In the previous week, Oragenics and Oragenics both had 2 articles in the media. Upexi's average media sentiment score of 0.34 beat Oragenics' score of 0.23 indicating that Upexi is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oragenics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Upexi
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Upexi beats Oragenics on 7 of the 11 factors compared between the two stocks.

Get Oragenics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OGEN vs. The Competition

MetricOragenicsPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$4.17M$6.47B$5.33B$19.29B
Dividend YieldN/A2.64%5.21%3.83%
P/E Ratio-0.039.0626.7734.52
Price / Sales104.31259.83393.2734.82
Price / CashN/A65.8538.2517.51
Price / Book0.326.456.774.69
Net Income-$20.66M$143.98M$3.23B$1.02B
7 Day Performance-2.85%0.38%0.43%-2.43%
1 Month Performance0.15%2.14%9.07%6.27%
1 Year Performance-91.09%-0.33%18.57%5.78%

Oragenics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OGEN
Oragenics
N/A$0.19
+1.2%
N/A-92.3%$4.17M$40,000.00-0.035
UPXI
Upexi
0.7259 of 5 stars
$10.64
+7.4%
N/A+45.1%$15.17M$18.63M0.00130News Coverage
Earnings Report
High Trading Volume
MBRX
Moleculin Biotech
1.9601 of 5 stars
$1.08
+2.9%
$6.00
+455.6%
-81.1%$15.12MN/A0.0020
NRSN
NeuroSense Therapeutics
2.6877 of 5 stars
$1.10
+5.4%
N/A+17.7%$15.03MN/A-1.7210Gap Up
INAB
IN8bio
2.9795 of 5 stars
$0.16
+3.6%
$6.00
+3,581.0%
-87.4%$14.80MN/A-0.2220Gap Up
FLGC
Flora Growth
2.4761 of 5 stars
$0.75
+10.5%
$5.00
+566.7%
-45.6%$14.58M$59.51M-0.57280
BCDA
BioCardia
2.7742 of 5 stars
$2.84
-0.4%
$25.00
+780.3%
-59.0%$14.47M$58,000.00-0.6840Gap Up
GOVX
GeoVax Labs
2.7841 of 5 stars
$0.93
-0.3%
$11.10
+1,099.9%
-45.5%$14.06M$5.59M-0.2510Positive News
EQ
Equillium
2.6089 of 5 stars
$0.39
-0.1%
$3.00
+669.2%
-72.3%$13.93M$41.10M-2.7940
EDSA
Edesa Biotech
2.6178 of 5 stars
$1.98
-3.4%
$21.00
+960.6%
-56.0%$13.91MN/A-1.0620Analyst Revision
LPTX
Leap Therapeutics
2.4159 of 5 stars
$0.38
+12.0%
$4.92
+1,210.8%
-85.2%$13.88MN/A-0.1940Positive News
Gap Up

Related Companies and Tools


This page (NYSE:OGEN) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners